BBOT BridgeBio Oncology Therapeutics Inc.
Healthcare$8.37-2.11%ClosedMarket Cap: $670.5M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.84
P/S
0.00
EV/EBITDA
-3.78
DCF Value
$11.88
FCF Yield
-25.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-61.5%
ROA
-36.9%
ROIC
-45.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-46.2M | $-42.1M | $— | — |
| Q4 null | $0.00 | NaN% | $-43.4M | $-38.8M | $— | — |
| FY null | $0.00 | NaN% | $-145.8M | $-134.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-49.2M | $-44.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-30.1M | $-28.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-23.1M | $-22.1M | $— | — |
| Q4 null | $0.00 | NaN% | $-21.9M | $-19.7M | $— | — |
| FY null | $0.00 | NaN% | $-80.9M | $-74.3M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-19.7M | $-17.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-23.9M | $-21.8M | $— | — |
| Q1 null | $0.00 | NaN% | $-15.4M | $-15.4M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-41.7K | $-41.7K | $-0.00 | — |